Pharmaceuticals: WYDEN: NIH IGNORED PATIENT, TAXPAYER COSTS FOR TAXOL
The National Institutes of Health had the authority to get a better deal for taxpayers and patients when it negotiated rights for the cancer drug Taxol, whose development relied heavily on NIH research. But the agency didn't use its clout to full advantage. That's the finding of a General Accounting Office analysis released by Sen. Ron Wyden (D-OR) June 6.
NIH's agreement allowing Bristol-Myers Squibb to patent the drug netted only $35 million in royalties for the government and failed to ensure that federally insured patients, particularly in Medicare, could buy it for affordable prices, even though the government...
To read the full article, sign in and subscribe to tci Medicare Compliance & Reimbursement.
Keep pace with evolving Medicare regulations — and onboard your team — with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI's Medicare Compliance & Reimbursement Alert will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, payer policies, the fee schedule, OIG target areas, and more.
Current newsletters added each month
Fully searchable archives - over 4200 articles
ALL years/issues back to 2003 organized by year and issue
Codes mentioned in articles are linked to Code Information pages
Code Information pages link back to related articles
Access to this feature is available in the following products: